Gilead Sciences, Inc.(GILD)
📅 Upcoming Dividend Payout
$0.79per Share
An upcoming dividend payment of $0.79 per share has been announced by Gilead Sciences, Inc., with the distribution date set for June 27, 2025.
Ex-Dividend Date:June 13, 2025
📊 Dividend Highlights
Previous Payout History
40 payouts shown| Pay Date | Amount Per Share | Change vs Previous |
|---|---|---|
| March 28, 2025 | $0.79 | ▲2.60% |
| December 30, 2024 | $0.77 | - |
| September 27, 2024 | $0.77 | - |
| June 27, 2024 | $0.77 | - |
| March 28, 2024 | $0.77 | ▲2.67% |
| December 28, 2023 | $0.75 | - |
| September 28, 2023 | $0.75 | - |
| June 29, 2023 | $0.75 | - |
| March 30, 2023 | $0.75 | ▲2.74% |
| December 29, 2022 | $0.73 | - |
| September 29, 2022 | $0.73 | - |
| June 29, 2022 | $0.73 | - |
| March 30, 2022 | $0.73 | ▲2.82% |
| December 30, 2021 | $0.71 | - |
| September 29, 2021 | $0.71 | - |
| June 29, 2021 | $0.71 | - |
| March 30, 2021 | $0.71 | ▲4.41% |
| December 30, 2020 | $0.68 | - |
| September 29, 2020 | $0.68 | - |
| June 29, 2020 | $0.68 | - |
| March 30, 2020 | $0.68 | ▲7.94% |
| December 30, 2019 | $0.63 | - |
| September 27, 2019 | $0.63 | - |
| June 27, 2019 | $0.63 | - |
| March 28, 2019 | $0.63 | ▲10.53% |
| December 28, 2018 | $0.57 | - |
| September 27, 2018 | $0.57 | - |
| June 28, 2018 | $0.57 | - |
| March 29, 2018 | $0.57 | ▲9.62% |
| December 28, 2017 | $0.52 | - |
| September 28, 2017 | $0.52 | - |
| June 29, 2017 | $0.52 | - |
| March 30, 2017 | $0.52 | ▲10.64% |
| December 29, 2016 | $0.47 | - |
| September 29, 2016 | $0.47 | - |
| June 29, 2016 | $0.47 | ▲9.30% |
| March 30, 2016 | $0.43 | - |
| December 30, 2015 | $0.43 | - |
| September 29, 2015 | $0.43 | - |
| June 29, 2015 | $0.43 |
Overall Dividend Trend
Dividend per share has changed by+83.72%over the past 10years(comparing first and last payout shown).
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a biopharmaceutical company founded in 1987, headquartered in Foster City, California. It's known for its research and development in antiviral drugs, particularly those used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. Gilead played a significant role during the COVID-19 pandemic with its antiviral medication, remdesivir. As of now, the CEO is Daniel O’Day, who took the helm in 2019. The company is widely recognized for its innovative approach in tackling complex health challenges and aims to improve patient care worldwide. In 2022, Gilead's revenue was approximately $27 billion, reflecting its strong market presence and the critical nature of its therapies.
AbbVie Inc.(ABBV)
Ligand Pharmaceuticals Incorporated(LGND)
Merck & Co., Inc.(MRK)
Moderna, Inc.(MRNA)
Pfizer Inc.(PFE)
Regeneron Pharmaceuticals, Inc.(REGN)
Vertex Pharmaceuticals Incorporated(VRTX)
Vir Biotechnology, Inc.(VIR)Dividend data last updated:Tue, 20 May 2025 21:37:49 GMT. Financial data is indicative and provided for informational purposes only.